Approach to pactamycin analogues using rhodium(II)- catalyzed alkene aziridination and C(sp 3 )-H amination reactions by Rodrigues, Romain et al.
HAL Id: hal-02366206
https://hal.archives-ouvertes.fr/hal-02366206
Submitted on 15 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Approach to pactamycin analogues using rhodium(II)-
catalyzed alkene aziridination and C(sp 3 )-H amination
reactions
Romain Rodrigues, Yanis Lazib, Julien Maury, Luc Neuville, David Leboeuf,
Philippe Dauban, Benjamin Darses
To cite this version:
Romain Rodrigues, Yanis Lazib, Julien Maury, Luc Neuville, David Leboeuf, et al.. Approach
to pactamycin analogues using rhodium(II)- catalyzed alkene aziridination and C(sp 3 )-H amina-
tion reactions. Organic Chemistry Frontiers, Royal Society of Chemistry, 2018, 5 (6), pp.948-953.
￿10.1039/c7qo00878c￿. ￿hal-02366206￿
Organic Chemistry Frontiers  
COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name .,  2013, 00 , 1-3 | 1   
Please do not adjust margins 
Please do not adjust margins 
a Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Univ. Paris-Sud, 
Université Paris-Saclay, 1, av. de la Terrasse, 91198 Gif-sur-Yvette, France. 
E-mail: philippe.dauban@cnrs.fr, benjamin.darses@cnrs.fr 
b Institut de Chimie Moléculaire et des Matériaux d'Orsay, CNRS UMR 8182, Univ. 
Paris-Sud, Université Paris-Saclay, bâtiment 420, 91405 Orsay cedex, France 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
Approach to pactamycin analogues using rhodium(II)-catalyzed 
alkene aziridination and C(sp3)—H amination reactions   
Romain Rodrigues,a Yanis Lazib,a Julien Maury,a,b Luc Neuville,a  David Leboeuf,b Philippe Dauban*a 
and Benjamin Darses*a
Dirhodium(II)-catalyzed nitrene transfers have been used to 
prepare a novel synthetic platform bearing the triamino moiety 
present in pactamycin, jogyamycin and cranomycin. Catalytic 
intramolecular C(sp3)-H amination and alkene aziridination 
reactions, the latter followed by a nucleophilic aziridine ring 
opening, are the key steps of this strategy.  
Introduction 
 
The genus Streptomyces has been a very productive source of 
biologically active molecules with original chemical structures. 
Among them, Pactamycin (Figure 1), which was first isolated 
from a fermentation broth of Streptomyces pactum var 
pactum, as a potential anticancer agent,1 was the first member 
of a fascinating aminocyclopentitol family. This natural 
antibiotic displays antimicrobial activities against gram-positive 
and gram-negative bacteria, as well as in vitro and in vivo anti-
proliferative activities, and anti-protozoal properties.2 The 
general cytotoxic effect arises from the interaction of 
Pactamycin with a highly conserved region of the small 
ribosomal subunit, causing the inhibition of the protein 
synthesis and the cell’s death.3 
In 2000, an X-ray crystallography study has revealed the nature 
of the interactions between Pactamycin and the ribosomal 30S 
subunit of Thermus thermophilus,4 allowing the identification 
of the functional groups responsible for the interaction with 
the ribosome small unit. Importantly, it can be highlighted that 
the C4 site, bearing the OH and the methyl group, would not be 
involved in any stabilizing interaction, and it was later shown 
that the absence of the methyl salicylate moiety does not 
modify the binding site between the ribosome and 
Pactamycin.5  
In 2011, the Pactamycin analogues TM-025 and TM-026, 
obtained by bioengineering, exhibited an improved profile, 
displaying a greater cytotoxicity against Plasmodium 
falciparum as compared to mammalian cells, however, specific 
analog design by this method is prohibited.6 Moreover, 
Jogyamycin,7 and Cranomycin (also called 7-
deoxypactamycin),8 two very closely related natural products, 
also confirmed that minute modifications at C6 and C7 could 
modify both the toxicity and the selectivity.  
 
The structural complexity of this aminocyclopentitol family and 
its relevant biological activities made its members stimulating 
targets for both synthetic and medicinal chemists. Different 
approaches to the partially functionalized core of Pactamycin 
or Jogyamycin have been thus reported.9,10 More significantly, 
the first total synthesis of Pactamycin including 32 steps was 
reported in 2011 by the group of Hanessian,11 followed two 
years later by a total synthesis completed in only 15 steps by 
the group of Johnson.12 
These two successful strategies prompted each group to 
develop novel Pactamycin analogs.13 These results, combined 
with the different X-ray crystallography information and the 
biosynthetic studies, afford valuable tools to design fine-tuned 
Pactamycin analogues with improved specific biological 
activity. 
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Figure 1  Pactamycin and biologically active aminocyclopentitols
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Over the last two decades, the field of nitrene addition 
reactions has considerably expanded.14 Following the initial 
discovery that transition metal complexes can react with 
iminoiodinanes to form metallanitrenes, practical procedures 
were described for the in situ generation of iminoiodinanes. 
This breakthrough made possible the development of catalytic 
C(sp3)–H amination and alkene aziridination reactions, as 
methods of choice for the synthesis of complex nitrogen-
containing natural and/or bioactive products.15 Accordingly, 
we and others have identified that the triamino moiety of 
Pactamycin and derivatives, could be introduced using 
sequential nitrene insertion reactions.9b,f,g,10 Indeed, the C1-C2 
1,2-diamino moiety could result from the ring opening of an 
aziridine, obtained by the tethered alkene aziridination 
reported by Du Bois and our group,16 while the C5 tertiary 
amino group could be introduced by an intramolecular C(sp3)–
H amination reaction (Scheme 1).17 Herein we report the 
application of this strategy to the preparation of the advanced 
synthetic intermediate 1, that could serve as a platform for the 
development simplified analogs of Pactamycin, Jogyamycin or 
Cranomycin. This intermediate could indeed allow tuning of 
the C7 center, key to the biological activity, and afford a never 
reported series of compounds bearing a methylene at C4.18 
 
Results and Discussion 
Preparation of the sulfamate 5 
 
Sulfamate 5 was identified as a first key intermediate in the 
synthesis of the pivotal product 1 (Scheme 2). Its preparation 
begins by the formation of the primary diol 2, directly 
accessible from norbornadiene following modification of the 
procedure reported by Rovis.19 Thus, use of the low boiling 
point methyl formate as solvent was found to greatly facilitate 
the manipulation of the unstable dialdehyde obtained by 
oxidative cleavage of the dihydroxynorbornene intermediate, 
and subsequent reduction with LiAlH4. It indeed prevents the 
need of a tedious work up involving an extraction of the 
hydrophilic diol 2 from water. Classical conditions for 
acetylation, then, allowed us to obtain the mono acetylated 
compound 3 in 53% yield,20 accompanied by 26% of recovered 
starting material 2 and 20% of diacetylated product 4, the 
latter being used to regenerate 2 in quantitative yield. The 
nitrene precursor was finally isolated in 90% yield after the 
sulfamoylation reaction using sulfamoyl chloride, generated 
from chlorosulfonyl isocyanate.  
 
Study of the aziridination reaction and the subsequent 
aziridine ring-opening 
 
With this key precursor in hand, the first catalytic nitrene 
transfer of our strategy was envisaged. The intramolecular 
alkene aziridination was performed in the presence of 1.3 
equivalents of PhI(OAc)2 and 1 mol % of Rh2(esp)2 (Scheme 3). 
Under these conditions, the expected aziridine 6 was isolated 
in 79% yield, accompanied by 10% of the tertiary C(sp3)-H 
amination product 7. A rapid screening of the dirhodium(II) 
complexes allowed us to determine that Rh2(CF3CONH)4 was 
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Scheme 2 Preparation of the nitrene precursor 5. Reaction 
conditions: (a) OsO4 0.4 mol %, NMO, pyridine, t-BuOH/H2O 
reflux, 15h, 71%; (b) NaIO4, HCO2Me/H2O, 0 °C to rt, 1h; (c) 
LiAlH4, THF, 0 °C to rt, 2h, 2 85% (2 steps); (d) Ac2O, Et3N, 
DCM, 0 °C to rt, 18h,  3 53%, 2 26% and 4 20%; (e) MeONa, 
MeOH, rt, 18h, 2 99%; (f) ClSO2NCO, HCO2H, 0 °C to rt, 16h 
then 3, DMA, pyridine, 0 °C to rt, 5h, 5 90%. NMO = 4-
methylmorpholine N-oxide; DMA = dimethylacetamide.
Scheme 1  Building the triamino moiety of 1  via nitrene insertions
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Scheme 4 Aziridine ring opening and recycling of 9. Reaction 
conditions: (a) TMSN3, TBAF cat., MeCN, rt, 8 63% and 9 32%; 
(b) H2(g), Pd/C cat., AcOEt; (c) NaNO2/H2O, THF/AcOH, 0 °C 
to rt, 6 42% (2 steps).
a
OAc
9
N
O S
O
O
OAc
6
NH
OAc
O S
NH
O
O
N3
N3
O
S
O
O +
b,c
1
2
8
Scheme 3 Rhodium(II)-catalyzed aziridination. Reaction 
conditions: (a) [Rh], PhI(OAc)2 1.3 equiv., MgO 1.9 equiv., 
DCM, 0 °C to rt, see table.
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the catalyst of choice to improve the chemoselectivity in favor 
of the aziridination product, the latter being isolated in 96% 
yield using this dirhodium(II) complex.21 Moreover, the catalyst 
loading could be reduced to 0.3 mol % without any loss of 
efficiency.  
The subsequent ring opening of the aziridine 6 proved to be 
more troublesome as the reaction with a nitrogen nucleophile 
showed poor regioselectivity. Extensive screening of 
nucleophiles, solvents, temperature and additives (see 
supplementary information for selected examples) led us to 
identify the combination of TMSN3 and a catalytic amount of 
TBAF in MeCN as the best combination of reagents. The 
expected product 8 was thus isolated in 63%, but accompanied 
by 32% of the undesired regioisomer 9 (Scheme 4). Pleasingly, 
with the aim to recycle the latter, we found that reduction of 
the azide followed by diazotization of the resulting crude 
amine led to recover the starting aziridine 6 with a non-
optimized yield of 42% over two steps. Formation of 6 results 
from the intramolecular substitution of the transient 
diazonium by the nitrogen of the sulfamate.22  
 
Study of the intramolecular C(sp3)—H amination reaction in 
the presence of the cyclic sulfamate 
We then planned to investigate the intramolecular C(sp3)-H 
amination of the tertiary C5 center. Many nitrene sources are 
available to perform such a transformation,14g,j and in order to 
favour the formation of the expected 5-membered ring, we 
decided to introduce a carbamate as the nitrene precursor. 
Starting from compound 8, the deacetylated intermediate 10 
was obtained in nearly quantitative yield and subsequent 
carbamoylation afforded 11 in 70% yield as the nitrene 
precursor for C(sp3)-H amination (Scheme 5).23 Unfortunately, 
a screening of the reaction conditions only allowed reaching 
20% of the expected product 12, and 25% of recovered 
starting material.24 Under all the tested reaction conditions, a 
high level of decomposition was observed. 
In order to try to improve the conversion, we turned our 
attention to the redox neutral conditions developed by Lebel.25 
The N-(sulfonyloxy)carbamate 13, thus, was prepared from the 
alcohol 10 in 60% yield over 3 steps (Scheme 6). However, the 
C(sp3)—H amination reaction proved to be even less satisfying 
with only 10% of the expected product 12 isolated and no 
starting material recovery.   
We identified the azido substituent as a potential unstable 
function responsible for the degradation of 14, and, thus, 
decided to reduce this group and protect it as a sulfonamide. 
The resulting compound 14 was isolated in 72% over two steps 
(Scheme 7). Submitting the latter to different C(sp3)–H 
amination reaction conditions proved to be much more 
rewarding, the expected product 15 being isolated in 50% yield 
in the presence of 20 mol % of Rh2(CF3CONH)4 and 1 equiv. of 
CF3CONH2. It is noteworthy that the degradation was limited, 
46% of the starting material being recovered. However, the 
very low solubility of 14 in a broad range of solvents has 
impeded the improvement upon screening of the reaction 
conditions. Traces of product 15 were obtained in the 
presence of common rhodium complexes in acetonitrile, a 
solvent in which compound 14 is soluble.  
We wondered whether the unexpected low turnover of the 
effective dirhodium complex could result from the presence of 
coordinating groups, likely to inhibit its catalytic activity. 
Accordingly, we have decided to remove the sulfamate moiety 
Scheme 6 C(sp3)-H amination using Lebel's protocol. Reaction 
conditions: (a) CDI,THF, rt, 3h; (b) NH2OH•HCl, pyridine, rt, 16h; 
(c) TsCl, Et3N, THF, 0 °C to rt, 6h, 13  60% (3 steps); (d) 
Rh2(OCOCPh3)4 6 mol %, K2CO3, DCM, rt, 12  10%.
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Scheme 7 Modification of the azide and C(sp3)-H amination. 
Reaction conditions: (a) H2(g), Pd/C cat., MeOH,  rt, 30 min.; (b) 
TsCl, Et3N, DMAP cat., MeCN, rt, 4h, 14 72% (2 steps); (c) TsCl, 
Et3N, THF, 0 °C to rt, 6h, 13  60%; (d) Rh2(NHCOCF3)4 20 mol 
%, CF3CONH2 1 equiv., PhI(OAc)2, MgO, rt, 12h, 15  50% and 14 
46%.
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Scheme 5 Preparation of 11  and C(sp3)-H amination. Reaction 
conditions: (a) MeONa, MeOH, rt, 30 min., 10  99%; (b) NaOCN, 
TFA, DCM, rt, 24h, 11  66%; (c) Rh2(NHCOCF3)4 10 mol %, 
Ph 2 hI(OR)2 1.5 equiv., MgO 3 equiv., solvent, 80 °C, see table. 
TCE = 1,1,2,2-tetrachloroethane.
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and replace it by orthogonal protecting groups, prone to 
improve the solubility of our intermediates. 
Therefore, after Boc activation of the nitrogen atom of 8, 
hydrolysis afforded 16 in 74% over two steps, 14% of the Boc-
protected sulfamate being also isolated (Scheme 8). 
Subsequent high yielding sequence of protection of the 
primary hydroxyl group as a silyl ether, acetyl group removal 
and carbamoylation led to the carbamate 17. Repeating the 
azide reduction and Ts protection strategy delivered the more 
soluble C(sp3)–H amination precursor 18. Indeed, extensive 
screening of the reaction conditions was possible with this 
intermediate. We found that the best conditions involve the 
use of 10 mol % of Rh2(OAc)4 in benzene at 50 °C, and in the 
presence of the hypervalent iodine reagent PhI(OCOCMe2Ph)2 
subtly developed by Du Bois in the course of his mechanistic 
studies of the Rh2(esp)2-catalyzed reaction.26 Under these 
conditions, the targeted pivotal product 19 (1 with R1 = Ts; R2 = 
Boc; R3 = TBDPS) was obtained in 63% yield.  
 
Conclusions 
 
In conclusion, we have designed a synthetic strategy from 
norbornadiene enabling the access to the novel platform 19 
displaying the triamino moiety present in the 
aminocyclopentitol congeners pactamycin, jogyamycin and 
cranomycin, with the correct relative stereochemistry. These 
aminated functional groups have been introduced by 
application of the synthetic nitrene chemistry and the 
dirhodium(II) catalysis: an intramolecular alkene aziridination 
followed by a nucleophilic aziridine ring opening delivers the 
1,2 diamino motif whereas an intramolecular C(sp3)-H 
amination reaction allows for introducing the tertiary amino 
center.27 Further work is currently under progress in our group 
to prepare new analogs of these bioactive natural products. 
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